BioSpace News Archive

CytoDyn Inc. announced Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference.

Arena Analytics, the market leader in applying artificial intelligence to workforce challenges, today announced strong 2021 results to date, including continued revenue growth, multiple new customer agreements, and an expanded leadership team.

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

In its recent report, Transparency Market Research gives intricate details about the global behavioral health market.

RELIEF THERAPEUTICS Holding SA reported that it has received scientific advice from the Medicines and Healthcare products Regulatory Agency in the United Kingdom relating to its lead investigational drug, RLF-100 TM, for the treatment of respiratory deficiency due to severe COVID-19.

Medivir AB announced that the Abstract entitled “Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma or liver metastases " has been released on the European Society for Medical Oncology website.

ITM AG, a leading radiopharmaceutical biotech company, announced that it has signed a strategic long-term agreement to create a Joint Venture with Chengdu Gaotong Isotope Co. Ltd., the leading provider of radiopharmaceuticals and nuclear services in China and a subsidiary of ITM’s collaboration partner China Isotope and Radiation Corporation.

Everest Medicines Limited announced two separate definitive agreements with Providence Therapeutics Holdings Inc. to license rights to Providence’s mRNA COVID-19 vaccine candidates in Asia emerging markets, including Greater China, Southeast Asia and Pakistan, and establish a broad, strategic partnership to develop mRNA products globally leveraging Providence’s cutting-edge mRNA technology platform.

Matinas BioPharma Holdings, Inc. announced positive efficacy and safety data from the first two cohorts of patients in the ongoing Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial of MAT2203 for the treatment of cryptococcal meningitis, which is being sponsored by the National Institute of Allergy and Infectious Diseases.

AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at $229 million, including certain development, regulatory and sales milestones.